发明申请
US20130252917A1 COMBINATION THERAPY OF 4-(3-(2H-1,2,3-TRIAZO-2-YL)PHENYLAMINO)-2-((1R,2S)-2-AMINOCYCLOHEXYLAMINO)PYRIMIDINE-5-CARBOXAMIDE AND FLUDARABINE
审中-公开
4-（3-（2H-1,2,3-三唑-2-基）苯基氨基）-2 - （（1R，2S）-2-氨基甲酰氧基]氨基] -5-羧酰胺和氟尿嘧啶的组合治疗
- 专利标题： COMBINATION THERAPY OF 4-(3-(2H-1,2,3-TRIAZO-2-YL)PHENYLAMINO)-2-((1R,2S)-2-AMINOCYCLOHEXYLAMINO)PYRIMIDINE-5-CARBOXAMIDE AND FLUDARABINE
- 专利标题（中）： 4-（3-（2H-1,2,3-三唑-2-基）苯基氨基）-2 - （（1R，2S）-2-氨基甲酰氧基]氨基] -5-羧酰胺和氟尿嘧啶的组合治疗
-
申请号： US13823710申请日： 2011-09-30
-
公开(公告)号： US20130252917A1公开(公告)日： 2013-09-26
- 发明人: Uma Sinha , Anjali Pandey
- 申请人： Uma Sinha , Anjali Pandey
- 申请人地址： US CA South San Francisco
- 专利权人： Portola Pharmaceuticals, Inc.
- 当前专利权人： Portola Pharmaceuticals, Inc.
- 当前专利权人地址： US CA South San Francisco
- 国际申请： PCT/US2011/054351 WO 20110930
- 主分类号： A61K31/7076
- IPC分类号： A61K31/7076 ; A61K31/506
摘要：
The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing 4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-(1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide, or a pharmaceutically acceptable salt thereof, and fludarabine for the treatment of cell proliferative disorders, such as undesired acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL); mantle cell lymphoma, acute lymphocytic leukemia (ALL), follicular lymphoma, Burkitt's lymphoma, small Lymphocytic Lymphoma (SLL) and multiple myeloma.
信息查询
IPC分类:
